Affimed Announces Presentation of Data on Genentech’s RO7297089 and AFM24, Both Innate Cell Engagers Developed from Affimed’s ROCK® Platform, at AACR Virtual Annual Meeting II June 22, 2020
Affimed Announces Successful Completion of First Dose Cohort in First-in-Human Phase 1/2A Study of AFM24 for the Treatment of Advanced EGFR-Expressing Solid Tumors Including Colon, Lung and Other Cancers June 17, 2020
Affimed to Report First Quarter 2020 Financial Results & Corporate Update June 23, 2020; Company to Participate in Virtual BMO Prescriptions for Success Healthcare Conference June 16, 2020
Affimed Highlights Study Design of its AFM13 REDIRECT Trial at the ASCO 2020 Virtual Meeting May 29, 2020
Affimed Announces Abstracts on Innate Cell Engagers from its ROCK® Platform Accepted for Presentation at AACR Virtual Annual Meeting II May 15, 2020
Affimed Announces First Patient Successfully Dosed in First-in-Human Phase 1/2A Study of AFM24 for the Treatment of Advanced EGFR-Expressing Solid Tumors Including Colon, Lung and Other Cancers April 16, 2020
